Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adaptive Trials Could Have A Steep Regulatory Learning Curve

Executive Summary

Sponsors should take care that drug development efficiencies gained with the advent of adaptive clinical trials aren't offset by lack of opportunity to reflect on data from one trial to the next and "design a thoughtful, complete program," FDA warns in its draft guidance for adaptive trial design
Advertisement

Related Content

FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
Adaptive Trials Guidance For Pediatric Drugs Will Draw On Device Advice
Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design
Best Practices For Adaptive Trial Designs Continue To Evolve
Sponsors’ Use Of Adaptive Designs Appears To Be Growing
FDA’s Guidance Document To-Do List
Better Use Of Phase II Trials Urged By FDA Statistician O'Neill
Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion
Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion
FDA Puts Hold On Adaptive Trials, Wants More Clarity On Basics

Topics

Advertisement
UsernamePublicRestriction

Register

PS051989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel